IAP 2023 Guidelines Enhance Malignancy Prediction for IPMN

The revised IAP 2023 guidelines significantly improved diagnostic performance for predicting malignancy in patients with branch-duct or mixed-type intraductal papillary mucinous neoplasms (IPMN). Among 556 reviewed patients, the guidelines displayed higher specificity (29.1% vs. 4.9% for IAP 2017), a positive predictive value of 48.6%, and greater accuracy (55.5% vs. 44.1%). These improvements could lead to decreased unnecessary surgeries compared to previous guidelines, potentially benefiting patient outcomes.